Solid Biosciences Inc
General ticker "SLDB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $208.5M
Solid Biosciences Inc does not follow the US Stock Market performance with the rate: -10.8%.
Estimated limits based on current volatility of 4.2%: low 3.95$, high 4.30$
Factors to consider:
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [2.98$, 8.69$]
- 2024-12-30 to 2025-12-30 estimated range: [3.44$, 9.31$]
Financial Metrics affecting the SLDB estimates:
- Negative: Non-GAAP EPS, $ of -4.84 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: negative Net income
- Negative: Operating cash flow per share per price, % of -52.43 <= 2.35
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
Short-term SLDB quotes
Long-term SLDB plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $13.62MM | $8.09MM | $0.00MM |
| Operating Expenses | $85.87MM | $114.55MM | $104.31MM |
| Operating Income | $-72.25MM | $-106.45MM | $-104.31MM |
| Non-Operating Income | $0.07MM | $20.47MM | $8.30MM |
| R&D Expense | $58.74MM | $78.42MM | $76.56MM |
| Income(Loss) | $-72.19MM | $-85.98MM | $-96.02MM |
| Profit(Loss) | $-72.19MM | $-85.98MM | $-96.02MM |
| Stockholders Equity | $208.21MM | $211.67MM | $126.48MM |
| Inventory | $6.01MM | $0.00MM | $0.00MM |
| Assets | $232.38MM | $260.25MM | $164.94MM |
| Operating Cash Flow | $-77.76MM | $-97.98MM | $-94.18MM |
| Capital expenditure | $1.28MM | $3.02MM | $1.51MM |
| Investing Cash Flow | $-91.09MM | $59.16MM | $9.69MM |
| Financing Cash Flow | $134.99MM | $74.83MM | $3.12MM |
| Earnings Per Share* | $-10.13 | $-7.70 | $-4.83 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.